- About us
- Clinical Trials
- News & Publications
- Business Development
PPF Group is one of the largest investment groups in Central and Eastern Europe which invests into multiple market segments, including banking and financial services, telecommunications, biotechnology, real estate, retail, insurance and agriculture. The PPF reach spans from Europe to Russia, the USA and across Asia. PPF Group owns assets of almost EUR 35 billion (as of 30 June 2017). For more information visit PPF Group.
SOTIO is leading the efforts of PPF Group to build a diverse biotechnology portfolio through its in-house SOTIO® research and development, collaborations with external partners, in-licensing deals, investments and acquisitions. For more information see the Business Development section.
As part of the PPF Group, SOTIO closely cooperates with its partners and drives pre-clinical and clinical development of the projects added to the SOTIO pipeline through external partnerships. The aim is to rapidly advance these projects to clinical trials and towards commercialization. To date, SOTIO has established partnerships with Cytune Pharma (France) regarding a novel interleukin-15 (IL-15) fusion protein program, NBE-Therapeutics (Switzerland) regarding a new Antibody-Drug Conjugate programs, and with Lead Discovery Center and Max Planck Innovation (Germany) regarding a first-in-class small molecule addressing an innovative tumor metabolism target. In addition to SOTIO, PPF also invested in Cytune Pharma, NBE-Therapeutics and Cellestia Biotech (Switzerland).